Open AccessImpact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients
Author(s) -
M L Avinash Tejasvi,
G Maragathavalli,
Uday Kumar Putcha,
Manasa Ramakrishna,
R. Vijayaraghavan,
C K Avinash
Publication year - 2020
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/ijpm.ijpm_964_19
Subject(s) - ercc1 , nucleotide excision repair , cisplatin , genotype , dna repair , oncology , single nucleotide polymorphism , cancer research , medicine , chemotherapy , gene , basal cell , biology , genetics
Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. The aim of this study was to investigate the association between polymorphisms in ERCC1 (C118T & C8092A) genes and the response to cisplatin-based chemotherapy.